LRIG1 Antibody [Alexa Fluor® 594]

• Reactivity: Mu
• Applications: WB, Flow, CyTOF-ready, ICC/IF
• Clonality: Polyclonal
• Host: Goat
• Conjugate: Alexa Fluor 594

LRIG1 Antibody [Alexa Fluor® 594] Summary

• Immunogen: Mouse myeloma cell line NS0-derived recombinant mouse LRIG1
  Ala37-Thr794
  Accession # P70193
• Specificity: Detects mouse LRIG1 in direct ELISAs and Western blots. In direct ELISAs, less than 10% cross-reactivity with recombinant human (rh) LRIG1 is observed and less than 5% cross-reactivity with rhLRIG3 is observed.
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat
• Purity Statement: Antigen Affinity-purified

Applications/Dilutions

• Dilutions:
  • CyTOF-ready
  • Flow Cytometry
  • Immunocytochemistry
  • Western Blot

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for LRIG1 Antibody [Alexa Fluor® 594]

• D6Bwg0781e
• Img
• LIG1
• LIG-1
• LRIG1

Background

LRIG-1 (leucine-rich repeats and Ig-like domains-1; also LIG-1) is an approximately 130-145 kDa glycoprotein that belongs to the LRIG gene family.  It is widely expressed, and appears on the surface of prostatic epithelium, endothelial cells, vascular and visceral smooth muscle, mammary epithelium, cardiac muscle, keratinocytes and neurons.  LRIG-1 is believed to negatively regulate the ErbB family of receptors.  In particular, and in a ligand-independent manner, LRIG-1 complexes with all four ErbBs, promoting their ubiquitination and decreasing their number.  Alternatively, LRIG-1 is suggested to bind to the ErbBs, preventing their dimerization and signal transduction.  Mature mouse LRIG-1 is a 1057 amino acid (aa) type I transmembrane protein (SwissProt #:P70193).  It contains a large 762 amino acid (aa) extracellular domain (ECD) (aa 35-795) plus a 274 aa cytoplasmic region.  The ECD contains 17 LRRs (aa’s 35-491) and three C2-type Ig-like domains (aa’s 497-781).  These two domain types are each sufficient for EGFR binding.  There one potential alternative splice form that a deletion of aa 875-923.  The LRIG-1 ECD undergoes proteolysis, generating 90-105 and 60-70 kDa soluble fragments.  Over aa 37-794, human LRIG-1 shares 97% and 90% aa sequence identity with rat and human LRIG-1, respectively.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.